Enasidenib Nitroso Impurity 2
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Enasidenib is used to treat acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation in patients who have not responded to other treatments or to those whose cancer has come back after treatment.Enasidenib Nitroso Impurity 2 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Enasidenib Nitroso Impurity 2 CAS NO: NA chemically represented as N-(4-((2-Hydroxy-2-methylpropyl)(nitroso)amino)-6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)nitrous amide. Synchemia is the leading manufacturing and exporter of Enasidenib Nitroso Impurity 2 . We supply Enasidenib Nitroso Impurity 2 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0142820 |
| CAS No | NA |
| Mol.F. | C10H16BN3O7S3 |
| Mol.Wt. | 397.24g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142821 |
| CAS No | NA |
| Mol.F. | C20H27N4O9S6 |
| Mol.Wt. | 659.82 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142822 |
| CAS No | NA |
| Mol.F. | C20H28N4O9S6 |
| Mol.Wt. | 660.82 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142823 |
| CAS No | NA |
| Mol.F. | C10H15N3O5S3 |
| Mol.Wt. | 353.43 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142824 |
| CAS No | NA |
| Mol.F. | C10H15N3O5S3 |
| Mol.Wt. | 353.43 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142825 |
| CAS No | NA |
| Mol.F. | C14H19N3O9S3 |
| Mol.Wt. | 469.50 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142826 |
| CAS No | NA |
| Mol.F. | C20H28N4O9S6 |
| Mol.Wt. | 660.82 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142827 |
| CAS No | 3028193-50-9 |
| Mol.F. | C20H20N2O2 |
| Mol.Wt. | 320.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142828 |
| CAS No | NA |
| Mol.F. | C18H24N4O6S2 |
| Mol.Wt. | 456.53g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142829 |
| CAS No | NA |
| Mol.F. | C20H28N4O8S3 |
| Mol.Wt. | 548.64 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142830 |
| CAS No | NA |
| Mol.F. | C20H28N4O8S3 |
| Mol.Wt. | 548.64 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142831 |
| CAS No | NA |
| Mol.F. | C10H165N3O4S |
| Mol.Wt. | 273.31g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142832 |
| CAS No | NA |
| Mol.F. | C24H23ClN2O2 |
| Mol.Wt. | 406.9 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142833 |
| CAS No | NA |
| Mol.F. | C22H24N4O8S |
| Mol.Wt. | 504.5 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142834 |
| CAS No | NA |
| Mol.F. | C23H24N4O10S |
| Mol.Wt. | 548.52g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142835 |
| CAS No | NA |
| Mol.F. | C22H26N4O9S |
| Mol.Wt. | 522.53 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |